Vertex Pharmaceutica
VRTX
Delayed Nasdaq - 05/25 10:00:00 pm
157.5USD
+0.34%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Discovers and develops novel, small molecule pharmaceuticals

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.

It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis.

The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Number of employees : 2 300 persons.
Sales per Businesses
20162017
USD
(in Million)
%USD
(in Million)
%
ORKAMBI979.5957.5%1,32153.1%
KALYDECO703.4341.3%844.6333.9%
INCIVEK0.6100%--
Sales per Regions
20162017
USD
(in Million)
%USD
(in Million)
%
United States1,32277.7%1,98779.8%
Europe320.4618.8%420.3216.9%
Other59.913.5%81.553.3%
United Kingdom----
Managers
Name Title
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Bruce I. Sachs Lead Independent Director
Elaine S. Ullian Lead Independent Director
Margaret G. McGlynn Independent Director
Terrence C. Kearney Independent Director
Yuchun Lee Independent Director
Shareholders
Name Equities %
T. Rowe Price Associates, Inc. 27,568,678 10.8%
The Vanguard Group, Inc. 17,934,295 7.04%
Fidelity Management & Research Co. 16,486,303 6.47%
BlackRock Fund Advisors 14,079,528 5.53%
Wellington Management Co. LLP 11,075,505 4.35%
SSgA Funds Management, Inc. 10,034,378 3.94%
Capital Research & Management Co. (World Investors) 8,998,927 3.53%
Jennison Associates LLC 6,775,328 2.66%
ClearBridge Investments LLC 6,390,726 2.51%
JPMorgan Investment Management, Inc. 5,943,108 2.33%
Company contact information
50 avenue Northern
MA 02110 Boston, Massachusetts
États-Unis (les)

Phone : +1 617 444 6100
Fax : +1 617 444 6680
Internet : http://www.vpharm.com
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- Nasdaq 100 / SP 500
Stock Exchange Codes
- Bloomberg Code :  VRTX:US
- Reuters Code :  VRTX.O
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS4.75%40 136
GILEAD SCIENCES-5.60%87 612
REGENERON PHARMACEUTICALS-21.45%31 122
GENMAB19.78%11 430
BEIGENE LTD (ADR)97.99%10 161
BLUEBIRD BIO INC1.77%9 430
NEUROCRINE BIOSCIENCES, INC.21.97%8 468
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.33.29%8 449
EXELIXIS, INC.-31.45%6 187
SAREPTA THERAPEUTICS INC59.89%6 006
BIOCON LTD22.98%5 846
HUALAN BIOLOGICAL ENGINEERING INC--.--%5 346
PEPTIDREAM INC20.87%5 327
AGIOS PHARMACEUTICALS INC56.31%5 148
BEIJING SL PHARMACEUTICAL CO LTD--.--%5 064
LOXO ONCOLOGY INC96.85%4 980
ARRAY BIOPHARMA INC22.19%3 347
ULTRAGENYX PHARMACEUTICAL INC40.79%3 346
ARGEN-X54.04%3 156
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO LTD--.--%3 153
SPARK THERAPEUTICS INC--.--%2 931